Expansion of Access to Investigational Drugs
There are cases in which pre-approval pharmaceuticals are used in clinical settings to treat diseases that greatly impact patient lives and for which existing treatment methods are ineffective. In these cases, we weigh the risks and benefits and will provide access to these pre-approval pharmaceuticals granted that the development of the pharmaceuticals in question will not be adversely impacted by this act.
Expansion of Access to Investigational Drugs
Patents in Countries and Regions Where Access to Healthcare is Insufficient
We prioritize improvement of access to healthcare so that we are flexible in applying and/or exercising patent rights within the necessary minimum range not to hinder access to healthcare.
Daiichi Sankyo Group Policy on Intellectual Property Rights and Access to Medicines in Developing Countries
Supply Chain Management
We strive for safety management and reliably and stably supply high quality medicines. In order to fulfill this responsibility, we aim to centralize information by integrating "functions to stably procure raw materials that customers can relieve and to produce as scheduled" and "logistics functions to deliver promptly and reliably after receipt of order" to build a flexible and efficient production and distribution system (supply chain management). Furthermore, under this structure, domestic and overseas production bases cooperate to fulfill a stable supply responsibility to the global market.
Quality & Steady Supply
Sustainable Procurement
Measures for Combating Counterfeit Pharmaceuticals
In response to the growing threat of counterfeit pharmaceuticals, we are reviewing the sealing materials and changing the specifications of individual packaging for items manufactured and sold by our company, as well as studying and introducing technologies to prevent counterfeit pharmaceuticals. In order to strengthen the traceability of our pharmaceutical products and medical narcotic products, we have completed compliance with the mandatory labeling of GS1 codes, which incorporate information on expiration dates and serial numbers, on each sales package and each original package. We will continue to work with the pharmaceutical industry and related organizations to examine the roles required of manufacturers and distributors and reinforcement measures in accordance with product risks.
We are also actively promoting compliance with GDP*1 to ensure the quality and integrity of our products during storage and transportation of pharmaceutical products. We are also striving to precisely respond in accordance with the regulations and risks in all countries and regions where we operate and are engaging in diligent study to ensure we can safely deliver pharmaceuticals to patients.
- *1Good Distribution Practice
Regional Access & Affordability
We strive to sell pharmaceuticals at appropriate prices based on the healthcare systems, insurance systems, and the standards of living of people in each country.
Regional Access & Affordability
Patient Assistance Programs
We will appropriately support patients, healthcare professionals, and other parties concerned (based on the various regulatory circumstances of each country), so that patients are encouraged to take their prescribed medications correctly.
Patient Assistance Programs
Generic Drugs
We are committed to offering affordable generic drugs that accurately address healthcare professional and patient needs. As it supplies these generic drugs, we take precautions to ensure quality and stable supplies while providing information to guarantee appropriate usage and maximum effectiveness.
American Regent, Inc.(US)